keyword
MENU ▼
Read by QxMD icon Read
search

lung adenocarcinoma brain metastases egfr

keyword
https://www.readbyqxmd.com/read/29172778/response-to-afatinib-in-treatment-na%C3%A3-ve-patients-with-advanced-mutant-epidermal-growth-factor-receptor-lung-adenocarcinoma-with-brain-metastases
#1
Shih-Hong Li, Chien-Ying Liu, Ping-Chih Hsu, Yueh-Fu Fang, Chun-Chieh Wang, Kuo-Chin Kao, Li-Chuan Tseng, Cheng-Ta Yang
BACKGROUND: Brain metastases are observable in 20-40% of non-small cell lung cancer patients, but standard treatments for such metastases may be intolerable to some. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were found to be effective against mutant-EGFR lung adenocarcinomas, but data regarding their effectiveness, especially for the second-generation EGFR-TKI afatinib, is limited. This study compared key outcomes for afatanib monotherapy versus afatinib combined with whole-brain radiotherapy (WBRT) in treatment-naïve lung adenocarcinoma patients harboring EGFR mutations...
December 2, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29163842/real-world-experience-of-afatinib-as-a-first-line-therapy-for-advanced-egfr-mutation-positive-lung-adenocarcinoma
#2
Sheng-Kai Liang, Min-Shu Hsieh, Meng-Rui Lee, Li-Ta Keng, Jen-Chung Ko, Jin-Yuan Shih
We evaluated the real-world efficacy and side effects of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. The medical records of patients receiving afatinib as a first-line therapy after National Health Insurance reimbursement between May 2014 and January 2016 were reviewed, and information on patient characteristics and treatment courses were collected consecutively. Rebiopsy tissue was collected for EGFR mutation and MET amplification analyses. MET amplification was detected by fluorescence in situ hybridization and immunohistochemistry...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29147576/erlotinib-intercalating-pemetrexed-cisplatin-versus-erlotinib-alone-in-chinese-patients-with-brain-metastases-from-lung-adenocarcinoma-a-prospective-non-randomised-concurrent-controlled-trial-nct01578668
#3
Haihong Yang, Qiuhua Deng, Yuan Qiu, Jun Huang, Yubao Guan, Fengnan Wang, Xin Xu, Xinyun Yang
Objective: Erlotinib has a synergistic effect with pemetrexed for treating non-squamous non-small-cell lung cancer. We investigated the efficacy and safety of erlotinib (E) in combination with pemetrexed/cisplatin (E-P) in Chinese patients with lung adenocarcinoma with brain metastases. Design: Patients who were erlotinib-naïve or pemetrexed-naïve were assigned in parallel to receive either E or E-P. The primary endpoint was the intracranial overall response rate (ORRi)...
2017: ESMO Open
https://www.readbyqxmd.com/read/29125233/in-vivo-imaging-xenograft-models-for-the-evaluation-of-anti-brain-tumor-efficacy-of-targeted-drugs
#4
Kenji Kita, Sachiko Arai, Akihiro Nishiyama, Hirokazu Taniguchi, Koji Fukuda, Rong Wang, Tadaaki Yamada, Shinji Takeuchi, Shoichiro Tange, Atsushi Tajima, Mitsutoshi Nakada, Kazuo Yasumoto, Yoshiharu Motoo, Takashi Murakami, Seiji Yano
Molecular-targeted drugs are generally effective against tumors containing driver oncogenes, such as EGFR, ALK, and NTRK1. However, patients harboring these oncogenes frequently experience a progression of brain metastases during treatment. Here, we present an in vivo imaging model for brain tumors using human cancer cell lines, including the EGFR-L858R/T790M-positive H1975 lung adenocarcinoma cells, the NUGC4 hepatocyte growth factor (HGF)-dependent gastric cancer cells, and the KM12SM colorectal cancer cells containing the TPM3-NTRK1 gene fusion...
November 10, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29070999/treatment-of-leptomeningeal-metastases-in-a-patient-with-non-small-cell-lung-cancer-harboring-egfr-t790m-mutation
#5
Hardy Niu, Junle Zhou, Harvinder Maan, Maurie Markman, Jiaxin Niu
BACKGROUND: Leptomeningeal metastasis (LM) is an uncommon complication in patients with solid tumors, associated with poor survival. However, LM appears to be more frequent in lung cancer patients with EGFR mutations, posing a unique clinical challenge to treating physicians. CASE PRESENTATION: We report the case of a 68-year-old Asian man with metastatic lung adenocarcinoma harboring an EGFR L858R mutation, which was initially treated with gefitinib. He developed disease progression 1 year later...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29061017/-impacts-of-egfr-19-exon-mutations-on-brain-metastases-in-treatment-na%C3%A3-ve-patients-with-lung-adenocarcinoma
#6
W L Wang, H W Li, J Z Cao, X Q Zhang, X Song, S F Jia, H X Jia
Objective: To investigate the relationship between the status of epidermal growth factor receptor (EGFR) mutations and brain metastases in patients with lung adenocarcinoma. Methods: From August 2010 to May 2015, a total of 1 063 lung adenocarcinoma patients with identified status of EGFR mutations in Shanxi Cancer Hospital were enrolled, of which 456 patients had EGFR mutations. Multivariate Logistic regression model was used to analyze the correlation between EGFR mutation status and brain metastases in patients with lung adenocarcinoma...
October 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/29050314/applicability-of-graded-prognostic-assessment-of-lung-cancer-using-molecular-markers-to-lung-adenocarcinoma-patients-with-brain-metastases
#7
Hongwei Li, Jianhong Lian, Songyan Han, Weili Wang, Haixia Jia, Jianzhong Cao, Xiaqin Zhang, Xin Song, Sufang Jia, Jiwei Ren, Weihua Yang, Yanfeng Xi, Shengmin Lan
Several scoring systems are available to estimate prognosis and assist in selecting treatment methods for non-small cell lung cancer (NSCLC) patients with brain metastasis, including recursive partitioning analysis (RPA), basic score for brain metastases (BS-BM), and diagnosis-specific graded prognostic assessment (DS-GPA). Lung-molGPA is an update of the DS-GPA that incorporates EGFR and/or ALK mutation status. The present study tested the applicability of these four indexes in 361 lung adenocarcinoma patients with brain metastasis...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28943548/afatinib-therapy-for-brain-metastasis-aggravated-by-a-reduction-in-the-dose-of-erlotinib-due-to-the-development-of-hepatotoxicity
#8
Yumie Yamanaka, Akimasa Sekine, Terufumi Kato, Hideaki Yamakawa, Satoshi Ikeda, Tomohisa Baba, Tae Iwasawa, Koji Okudela, Takashi Ogura
We report an 80-year-old woman with EGFR-mutant lung adenocarcinoma with multiple brain metastases (BMs). All lesions including BM showed a successful resolution after initiating daily 150 mg erlotinib. However, a grade 2 bilirubin-increase developed, and it was necessary to reduce the dose of erlotinib to 50 mg every other day, which aggravated BM. Switching erlotinib to afatinib led to the resolution of BM without an increase in the bilirubin level. Our results indicate that afatinib is an important treatment option when erlotinib-induced hepatotoxicity develops, regardless of the patients' age...
September 25, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28780743/high-probability-and-frequency-of-egfr-mutations-in-non-small-cell-lung-cancer-with-brain-metastases
#9
Mengxi Ge, Yingjie Zhuang, Xinli Zhou, Ruofan Huang, Xiaohua Liang, Qiong Zhan
Lung cancer is the leading cause of cancer death in men and women worldwide. Brain metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of death. This study aimed to explore the association of epidermal growth factor receptor (EGFR) mutations and BMs in NSCLC. We analyzed 50 NSCLC patients with BMs and 50 match-paired NSCLC patients with no brain metastases (NBMs). The EGFR mutation status of primary lesions was detected using the amplification refractory mutation system polymerase chain reaction...
November 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28767414/real-world-experience-of-afatinib-as-a-first-line-therapy-for-advanced-egfr-mutation-positive-lung-adenocarcinoma
#10
Sheng-Kai Liang, Min-Shu Hsieh, Meng-Rui Lee, Li-Ta Keng, Jen-Chung Ko, Jin-Yuan Shih
We evaluated the real-world efficacy and side effects of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. The medical records of patients receiving afatinib as a first-line therapy after National Health Insurance reimbursement between May 2014 and January 2016 were reviewed, and information on patient characteristics and treatment courses were collected consecutively. Rebiopsy tissue was collected for EGFR mutation and MET amplification analyses. MET amplification was detected by fluorescence in situ hybridization and immunohistochemistry...
July 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28717762/epidermal-growth-factor-receptor-mutational-status-and-brain-metastases-in-non-small-cell-lung-cancer
#11
Vijaya Raj Bhatt, Sanyo P D'Souza, Lynette M Smith, Allison M Cushman-Vokoun, Vanita Noronha, Vivek Verma, Amit Joshi, Anuradha Chougule, Nirmala Jambhekar, Anne Kessinger, Alissa Marr, Vijay Patil, Sripad D Banavali, Apar Kishor Ganti, Kumar Prabhash
INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancers (NSCLC) may be more common in patients with brain metastases. Previous studies, however, did not adjust for effects of confounding variables. METHODS: This retrospective study included 1,522 consecutive patients with NSCLC, whose tumors were diagnosed and tested for EGFR mutations at the University of Nebraska Medical Center (Omaha, NE) and Tata Memorial Hospital (Mumbai, India)...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28651600/validation-of-the-graded-prognostic-assessment-for-lung-cancer-with-brain-metastases-using-molecular-markers-lung-molgpa
#12
Carsten Nieder, Mandy Hintz, Oliver Oehlke, Angelika Bilger, Anca L Grosu
BACKGROUND: Many patients with brain metastases from non-small cell lung cancer have limited survival, while others survive for several years, depending on patterns of spread, EGFR and ALK alterations, among others. The purpose of this study was to validate a new prognostic model (Lung-molGPA) originally derived from a North American database. PATIENTS AND METHODS: This retrospective study included 269 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy...
June 26, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28597503/prognostic-model-for-brain-metastases-from-lung-adenocarcinoma-identified-with-epidermal-growth-factor-receptor-mutation-status
#13
Hongwei Li, Weili Wang, Haixia Jia, Jianhong Lian, Jianzhong Cao, Xiaqin Zhang, Xing Song, Sufang Jia, Zhengran Li, Xing Cao, Wei Zhou, Songye Han, Weihua Yang, Yanfen Xi, Shenming Lian
BACKGROUND: Several indices have been developed to predict survival of brain metastases (BM) based on prognostic factors. However, such models were designed for general brain metastases from different kinds of cancers, and prognostic factors vary between cancers and histological subtypes. Recently, studies have indicated that epidermal growth factor receptor (EGFR) mutation status may be a potential prognostic biological factor in BM from lung adenocarcinoma. Thus, we sought to define the role of EGFR mutation in prognoses and introduce a prognostic model specific for BM from lung adenocarcinoma...
September 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28540256/concurrent-afatinib-and-whole-brain-radiotherapy-in-exon-19-del-egfr-mutant-lung-adenocarcinoma-a-case-report-and-mini-review-of-the-literature
#14
Chukwuka Eze, Nina-Sophie Hegemann, Olarn Roengvoraphoj, Maurice Dantes, Farkhad Manapov
Leptomeningeal metastases (LM) are found in approximately 3.8% of non-small cell lung cancer cases with an increased incidence in adenocarcinoma, and approximately one-third of patients will present with concomitant brain metastases. We report the case of a 50-year-old male patient with stage IV exon 19-del-EGFR mutant lung adenocarcinoma who progressed on second-generation TKI therapy with manifestation of symptomatic simultaneous diffuse brain and LM. Whole-brain radiotherapy with concurrent afatinib resulted in an almost complete regression of neurological symptoms as well as good, durable radiological response...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28413660/dramatic-intracranial-response-to-osimertinib-in-a-poor-performance-status-patient-with-lung-adenocarcinoma-harboring-the-epidermal-growth-factor-receptor-t790m-mutation-a-case-report
#15
Takehiro Uemura, Tetsuya Oguri, Minami Okayama, Hiromi Furuta, Yoshihiro Kanemitsu, Osamu Takakuwa, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio Niimi
We herein report a case of dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor (EGFR) T790M mutation encoded in exon 20. The patient was a 59-year-old woman with EGFR exon 19 deletion-positive lung adenocarcinoma, who relapsed with multiple brain metastases. Computed tomography-guided biopsy of the left pleural tumor revealed adenocarcinoma harboring an EGFR exon 19 deletion and an EGFR T790M mutation encoded in exon 20...
April 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28412028/-effectiveness-of-erlotinib-in-critical-care-unit-in-patients-with-non-small-cell-lung-cancer-with-egfr-mutation
#16
M Dewolf, C Dayen, C Garoute, W Khamis, M Fourrier, F Rousselle, M Sadki, F Le Meunier, R Suguenot, E Lecuyer, H Bentayeb, Y Douadi, P Berna
INTRODUCTION: The search for mutations epidermal growth factor receptor (EGFR) has changed the therapeutic approach and prognosis of non-small cell lung cancer (NSCLC). The effectiveness of tyrosine kinase inhibitors (TKI) has been demonstrated orally in patients with EGFR mutation. We report the case of a patient for whom treatment with TKI was started effectively in a Critical Care Unit. OBSERVATION: A patient of 59 years is followed for a stage IV lung adenocarcinoma with metastases in liver, brain, adrenal, lung and pleura...
June 2017: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/28391386/assessment-of-prognostic-scores-of-brain-metastases-from-lung-adenocarcinoma-with-egfr-mutations
#17
Hongwei Li, Jianhong Lian, Hongxing Jin, Weili Wang, Jianzhong Cao, Xiaqin Zhang, Xin Song, Sufang Jia, Haixia Jia, Jiwei Ren, Songyan Han, Weihua Yang, Yanfeng Xi, Shengmin Lan
The aim of this study was to analyze prognostic factors and evaluate the value of four prognostic scores including RPA, DS-GPA BS-BM, GGS for the EGFR mutant BM patients from lung adenocarcinoma treated with EGFR-TKI. Data of NSCLC were retrospectively reviewed from August 2010 to June 2015 using the medical database of Shanxi Provincial Cancer Hospital. Patients with BM from lung adenocarcinoma with mutant EGFR treated by EGFR-TKI or a combination of EGFR-TKI and WBRT were included. Potential prognostic factors were statistically examined...
May 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28332624/effects-of-icotinib-with-and-without-radiation-therapy-on-patients-with-egfr-mutant-non-small-cell-lung-cancer-and-brain-metastases
#18
Yun Fan, Yanjun Xu, Lei Gong, Luo Fang, Hongyang Lu, Jing Qin, Na Han, Fajun Xie, Guoqin Qiu, Zhiyu Huang
EGFR-TKIs and radiation therapy (RT) are the principal treatment for patients with brain metastases (BM) and EGFR mutant NSCLC. However, the optimal use of brain RT for patients with asymptomatic BM remains undefined. A total of 152 patients were identified. 58 patients were excluded. Of the remaining 97 patients, 56 patients received upfront RT followed by icotinib, including WBRT or SRS. 41 patients received icotinib therapy alone. The mOS from diagnosis of BM was 27.0 months for the whole cohort (95% CI, 23...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28254368/the-impact-of-tumor-biology-on-survival-and-response-to-radiation-therapy-among-patients-with-non-small-cell-lung-cancer-brain-metastases
#19
Jacob A Miller, Rupesh Kotecha, Manmeet S Ahluwalia, Alireza M Mohammadi, John H Suh, Gene H Barnett, Erin S Murphy, Michael A Vogelbaum, Lilyana Angelov, Samuel T Chao
PURPOSE: To investigate the natural history and response to radiation therapy among ALK-rearranged, EGFR-mutated, wild-type adenocarcinoma, and squamous cell non-small cell lung cancer (NSCLC) brain metastases. METHODS AND MATERIALS: Patients with NSCLC brain metastasis diagnosed from 1989 through 2014 at a single tertiary-care institution were included. The primary outcome was overall survival, whereas secondary outcomes included local failure, distant intracranial failure, and radiation necrosis...
July 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28228223/-clinical-experience-with-first-generation-epidermal-growth-factor-receptor-%C3%A2-tyrosine-kinase-inhibitors-in-non-small-cell-lung-cancer-patients-%C3%A2-with-brain-metastasis
#20
Huixing Dong, Shaohua Cui, Feng Pan, Lili Dong, Yanjie Niu, Yizhuo Zhao, Aiqin Gu, Xiaoyan Jin, Liyan Jiang
BACKGROUND: A survival analysis and the influencing factors for non-small cell lung cancer (NSCLC) patients with brain metastases accepting first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) treatment have not yet been elucidated to date. In this study, we collected and analyzed the survival data of NSCLC patients with brain metastasis to obtain evidence and to provide guidance in clinical practice. METHODS: NSCLC patients with brain metastases who were treated with first-generation EGFR-TKIs were retrospectively collected in 2012-2013 from Shanghai Chest Hospital, Shanghai Jiao Tong University...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
keyword
keyword
98956
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"